Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Qiagen N.V. (QGEN)

46.15   0.32 (0.7%) 03-24 16:00
Open: 45.95 Pre. Close: 45.83
High: 46.15 Low: 45.58
Volume: 532,212 Market Cap: 10,509(M)

Technical analysis

as of: 2023-03-24 4:29:08 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 54.76     One year: 56.07
Support: Support1: 45.08    Support2: 37.5
Resistance: Resistance1: 46.89    Resistance2: 48
Pivot: 46.1
Moving Average: MA(5): 46.03     MA(20): 46.06
MA(100): 48.07     MA(250): 46.78
MACD: MACD(12,26): -0.5     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 39.9     %D(3): 47.6
RSI: RSI(14): 44.5
52-week: High: 51.18  Low: 40.38
Average Vol(K): 3-Month: 656 (K)  10-Days: 703 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ QGEN ] has closed below upper band by 45.0%. Bollinger Bands are 71.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 46.22 - 46.47 46.47 - 46.71
Low: 44.89 - 45.23 45.23 - 45.54
Close: 45.65 - 46.15 46.15 - 46.61

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Headline News

Sun, 26 Mar 2023
Pendal Group Ltd Has $214.56 Million Holdings in Qiagen (NYSE ... - MarketBeat

Fri, 24 Mar 2023
The Math Shows ONEV Can Go To $117 - Nasdaq

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On David Dreman - 3 ... - Nasdaq

Tue, 14 Mar 2023
Should You Sell Qiagen NV (QGEN) Stock Tuesday Morning? - InvestorsObserver

Mon, 13 Mar 2023
QIAGEN Announces Form 20-F Annual Report Filing for 2022 ... - Benzinga

Thu, 09 Mar 2023
QIAGEN and Servier Partner to Develop Companion Diagnostic for ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 228 (M)
Shares Float 226 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 72.2 (%)
Shares Short 5,170 (K)
Shares Short P.Month 5,350 (K)

Stock Financials

EPS 1.83
EPS Est Next Qtl 0.41
EPS Est This Year 1.17
EPS Est Next Year 1.32
Book Value (p.s.) 15.22
Profit Margin (%) 19.7
Operating Margin (%) 26.9
Return on Assets (ttm) 5.8
Return on Equity (ttm) 12.8
Qtrly Rev. Growth -14.5
Gross Profit (p.s.) 6.36
Sales Per Share 9.39
EBITDA (p.s.) 3.39
Qtrly Earnings Growth -30.8
Operating Cash Flow 715 (M)
Levered Free Cash Flow 448 (M)

Stock Valuations

PE Ratio 25.21
PEG Ratio -5.5
Price to Book value 3.03
Price to Sales 4.91
Price to Cash Flow 14.69

Stock Dividends

Dividend 1.09
Forward Dividend 0
Dividend Yield 2.3%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.